Lexeo Therapeutics Inc

Research Lexeo Therapeutics Inc (LXEO) on Bullrun: market cap USD 377.69M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerLXEO
• ExchangeNASDAQ
• CountryUnited States
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Market capUSD 377.69M
• Financial periodFY2025
• Net income-USD 100.00M
• Free cash flow-USD 98.96M

Valuation Snapshot

latest market cap is USD 377.69M.

About Lexeo Therapeutics Inc

Lexeo Therapeutics, Inc., a clinical stage genetic medicine company, focuses on hereditary and acquired diseases with high unmet need in the United States. Its product pipeline comprises LX2006, an AAVrh10-based gene therapy candidate, which is in phase 1/2 clinical trial to treat friedreich ataxia cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate, which is in phase 1/2 to deliver a functional plakophilin-2 (PKP2) gene to cardiac muscle for the treatment of PKP2-ACM;

Frequently asked questions

What is Lexeo Therapeutics Inc's market cap?

Lexeo Therapeutics Inc's market capitalization is USD 377.69M.

What does Lexeo Therapeutics Inc do?

Lexeo Therapeutics, Inc., a clinical stage genetic medicine company, focuses on hereditary and acquired diseases with high unmet need in the United States.